Indegene Limited (IN:INDGN)
:INDGN
Want to see IN:INDGN full AI Analyst Report?
INDGN Stock Chart & Stats
₹522.25
₹9.00(1.45%)
At close: 4:00 PM EST
₹522.25
₹9.00(1.45%)
Day’s Range― - ―
52-Week Range₹414.90 - ₹632.10
Previous CloseN/A
Volume943.30K
Average Volume (3M)17.62K
Market Cap
₹118.29B
Enterprise Value₹117.93B
Total Cash (Recent Filing)₹12.68B
Total Debt (Recent Filing)₹2.10B
Price to Earnings (P/E)30.3
Beta0.47
Next Earnings
Jun 03, 2026EPS Estimate
4.55Next Dividend Ex-DateN/A
Dividend Yield0.38%
Share Statistics
EPS (TTM)4.30
Shares Outstanding240,901,350
10 Day Avg. Volume12,460
30 Day Avg. Volume17,622
Financial Highlights & Ratios
PEG Ratio1.56
Price to Book (P/B)5.26
Price to Sales (P/S)4.85
P/FCF Ratio33.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹525.00Price Target Upside0.53% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)21.29
Revenue Forecast (FY)₹42.19B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthAn ~18.4% revenue growth rate indicates durable demand for Indegene's technology-enabled services and expanding client engagements. Sustained top-line expansion supports scale economics, strengthens cross-sell opportunities across commercial, medical, analytics and platform offerings, and underpins recurring managed-service revenue over multiple quarters.
High Margins And ProfitabilityConsistently strong gross and operating margins point to pricing power and a scalable service model in regulated life-sciences markets. High margins improve cash conversion and fund reinvestment into platforms and capabilities, making the business more resilient to cyclicality and enabling sustainable investment in product and people over the medium term.
Strong Balance SheetA strong equity base and low leverage provide financial flexibility to fund organic growth, platform development and selective M&A without stressing liquidity. Reduced total debt and rising assets lower solvency risk, support multi-quarter client deployments in regulated markets, and help absorb temporary cash-flow variability.
Bears Say
2025 EBITDA DeclineA sharp EBITDA drop in 2025 signals potential margin pressure from adverse contract mix, pricing compression, or cost increases. If this is structural rather than one-off, it could weaken cash generation, force tighter cost controls, and reduce headroom for platform investment and talent retention over subsequent quarters.
Cash Flow VolatilityInconsistent free cash flow growth and volatile investing/financing flows constrain predictable capital allocation. This uneven cash profile limits the company’s ability to fund long-term platform builds or acquisitions internally, increases reliance on external financing during downturns, and raises execution risk for multi-quarter initiatives.
Net Income InconsistencyVariable net income reduces forecasting reliability and may reflect client concentration, lumpy project timing, or episodic costs. Persistent earnings volatility complicates multi-quarter planning, weakens investor visibility into sustainable cash flows, and can hinder long-term investments or hiring plans if unpredictability remains.
Indegene Limited News
INDGN FAQ
What was Indegene Limited’s price range in the past 12 months?
Indegene Limited lowest stock price was ₹414.90 and its highest was ₹632.10 in the past 12 months.
What is Indegene Limited’s market cap?
Indegene Limited’s market cap is ₹118.29B.
When is Indegene Limited’s upcoming earnings report date?
Indegene Limited’s upcoming earnings report date is Jun 03, 2026 which is in 35 days.
How were Indegene Limited’s earnings last quarter?
Indegene Limited released its earnings results on Jan 29, 2026. The company reported ₹4.3 earnings per share for the quarter, missing the consensus estimate of ₹5.15 by -₹0.85.
Is Indegene Limited overvalued?
According to Wall Street analysts Indegene Limited’s price is currently Undervalued.
Does Indegene Limited pay dividends?
Indegene Limited pays a Notavailable dividend of ₹2 which represents an annual dividend yield of 0.38%. See more information on Indegene Limited dividends here
What is Indegene Limited’s EPS estimate?
Indegene Limited’s EPS estimate is 4.55.
How many shares outstanding does Indegene Limited have?
Indegene Limited has 240,901,350 shares outstanding.
What happened to Indegene Limited’s price movement after its last earnings report?
Indegene Limited reported an EPS of ₹4.3 in its last earnings report, missing expectations of ₹5.15. Following the earnings report the stock price went down -1.262%.
Which hedge fund is a major shareholder of Indegene Limited?
Currently, no hedge funds are holding shares in IN:INDGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indegene Limited
Indegene Limited operates as a life sciences commercialization company in India and internationally. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get to the market, and grow impact through the life cycle. The company offers enterprise commercial solutions, enterprise medical solutions, enterprise clinical solutions, omnichannel activation solutions, and NEXT technology platforms. The company was incorporated in 1998 and is based in Bengaluru, India.
INDGN Stock 12 Month Forecast
Average Price Target
₹525.00
▲(0.53% Upside)
Technical Analysis
Birlasoft Limited
―
Cyient Limited
―
Latent View Analytics Limited
―
Tanla Platforms Ltd
―
Zensar Technologies Limited
―